Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-Ketami

Phase 1

• Conditions: Intrathecal S(+)-ketamine is a potent option in the treatment of chronic severe neuropathic pain in cancer patients refractory to conventional therapeutic strategies (Benrath et al. 2005). However, the lack of systematic safety data limit the neuraxial administration of S(+)-ketamine.Benrath J, Scharbert G, Gustorff B, Adams HA, Kress HG. Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain. Br J Anaesth 2005; 95:247-9.

• Registration Number: EUCTR2006-000767-28-AT
• Lead Sponsor: Vienna Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08-29
• Last Update Posted: 14 November 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

chronic, refractory, neuropathic cancer pain
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

contraindications against ketamine

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified